التفاصيل البيبلوغرافية
| العنوان: |
Updated analysis of phase 2 study of bendamustine and dexamethasone in patients with relapsed/refractory systemic light chain (AL) amyloidosis. |
| المؤلفون: |
Lentzsch, Suzanne1 (AUTHOR) sl3440@cumc.columbia.edu, Lagos, Galina G.1 (AUTHOR), Comenzo, Raymond L.2 (AUTHOR), Zonder, Jeffrey A.3 (AUTHOR), Pregja, Silva3 (AUTHOR), Osman, Keren4 (AUTHOR), Tsai, Wei-Yann1 (AUTHOR), Landau, Heather5 (AUTHOR), Sanchorawala, Vaishali6 (AUTHOR) |
| المصدر: |
Amyloid. 2019 Supplement 1, Vol. 26, p113-114. 2p. |
| مصطلحات موضوعية: |
*CARDIAC amyloidosis, *CLINICAL trial registries, *PROGRESSION-free survival, *DEXAMETHASONE, *CHRONIC lymphocytic leukemia |
| مستخلص: |
Highlights from the article: Patients with relapsed or refractory AL amyloidosis have limited treatment options. Out of 23 patients with evaluable organ response, 5 of 13 patients had a renal response and 1 of 14 patients had cardiac response. In patients with refractory and/or relapsed AL amyloidosis with limited therapeutic options Ben/Dex is a viable treatment option that produced a substantial hematologic response and increased survival. |
| قاعدة البيانات: |
Academic Search Index |
